Home About Us Pipeline News Investors Contacts Careers


News

Recent Press Releases Archives

Recent Press Releases

2019 News Releases

November 6, 2019 - Puma Biotechnology Reports Third Quarter 2019 Financial Results
Read

November 5, 2019 - Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer
Read

November 4, 2019 - Puma Biotechnology to Present at the Credit Suisse Healthcare Conference
Read

October 23, 2019 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Read

October 3, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

October 2, 2019 - FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

September 25, 2019 - Puma Biotechnology to Present at Cantor Global Healthcare Conference
Read

September 11, 2019 - Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Read

September 5, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

September 4, 2019 - Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer
Read

September 3, 2019 - FDA Grants Orphan Drug Designation to Puma Biotechnology’s NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases
Read

September 3, 2019 - Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Read

August 8, 2019 - Puma Biotechnology Reports Second Quarter 2019 Financial Results
Read

August 6, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

July 25, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

July 24, 2019 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Read

July 16, 2019 - Puma Biotechnology’s Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast Cancer
Read

July 3, 2019 - Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019
Read

July 1, 2019 - Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Read

June 5, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

June 4, 2019 - Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2 Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting
Read

June 2, 2019 - Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting
Read

May 29, 2019 - Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference
Read

May 9, 2019 - Puma Biotechnology Reports First Quarter 2019 Financial Results
Read

May 8, 2019 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019
Read

April 25, 2019 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
Read

April 9, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

April 4, 2019 - Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations
Read

April 1, 2019 - Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe
Read

March 28, 2019 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019
Read

March 18, 2019 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting - Oral Plenary Presentation Receives SGO Presidential Award
Read

March 18, 2019 - Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
Read

March 5, 2019 - Puma Biotechnology to Present at Cowen’s Annual Health Care Conference
Read

February 28, 2019 - Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results
Read

February 15, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read

February 13, 2019 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results
Read

February 4, 2019 - Puma Biotechnology Announces Litigation Victory with Jury’s Decision
Read

January 11, 2019 - Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada
Read

January 3, 2019 - Puma Biotechnology to Present at J. P. Morgan Healthcare Conference
Read

January 2, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Read




Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax